Oct 19, 2017 8:00 am EDT Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
Oct 16, 2017 8:00 am EDT Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)
Sep 11, 2017 8:00 am EDT Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129
Aug 22, 2017 4:35 pm EDT Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 22, 2017 8:00 am EDT Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
Aug 07, 2017 4:05 pm EDT Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights
Aug 02, 2017 8:00 am EDT Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
Jul 31, 2017 8:10 am EDT Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS)